Finance
S&P 500 7,757.17 +44.60 +0.58% Dow 52,856.09 +360.19 +0.69% Nasdaq 26,702.86 +278.04 +1.05% NYSE Composite 24,253.12 +62.52 +0.26% Russell 2000 2,781.02 +7.60 +0.27% VIX 16.68 -0.63 -3.64%

ANEB · Anebulo Pharmaceuticals, Inc.

OTC MARKETS - BOATS Real Time Price • USD

Anebulo Pharmaceuticals Inc (ANEB)

OTC MARKETS Pharmaceuticals
Move probability → Options chain →
$0.37 -0.07 (-15.33%)
● At close: February 27 at 4:00:00 PM EDT
DAY'S RANGE $0.37
$0.37 $0.43
52-WEEK RANGE $0.37
$0.00 $2.85

What's happening

Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.

Key Statistics

Market Cap$11.8M
P/E (TTM1)—
EPS2 (TTM)$-0.19
Div Yield—
Beta3-2.01
Volume1,370
Open0.43
Prev Close0.44
Bid / Ask0.35 / 3.33
Next Earnings 2026-11-11

Analyst Recommendations

Strong buy 0 Buy 0 Hold 3 Sell 1 Strong sell 2

Aggregate ratings for 2026-06-01 (6 analysts polled by Finnhub) — consensus count.

Performance Overview (Trailing returns vs S&P 500 benchmark)

YTD RETURN
ANEB -99.93%
vs S&P 500 -110.75%
1-YEAR RETURN
ANEB -5.49%
vs S&P 500 -16.52%
6-MONTH RETURN
ANEB -99.93%
3-MONTH RETURN
ANEB -99.80%

Valuation Measures & Ratios

Enterprise Value4$2.8M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book75.23
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-75.39%
Return on Assets (ROA9)-68.98%
Avg Volume (3M)1,030
Quarterly history (5 periods)
Measure Dec '25Sep '25Mar '25Dec '24Sep '24
Market cap $40.0M $102.3M $56.6M $47.1M —
P/E -4.82 -12.04 -7.08 -5.21 —
Price/Book 5.04 10.51 4.20 3.15 —
ROE -104.54% -87.28% -59.38% -60.38% —
ROA -88.06% -79.42% -57.06% -57.03% —

Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).

Glossary — what these abbreviations mean
1. TTM
Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
2. EPS
Earnings per share — net income divided by diluted shares outstanding.
3. Beta
A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
4. EV (Enterprise Value)
Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
5. Forward P/E
Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
6. PEG Ratio
P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
7. Price / Book
Share price divided by book value (assets minus liabilities) per share.
8. ROE
Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
9. ROA
Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
10. MRQ
Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
11. YoY
Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.

Short Interest

Shares Short390,808
Change from Prior Settlement-0.05%
% of Float—
Days to Cover (Short Ratio)626.29

Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.

Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.

Price history

Events

Drag horizontally to zoom into a section; use Reset view to restore all observations.

Technical signal summary

Calculating from the latest year of daily price history…

Calculating…
Show Technical Analysis Breakdown ▾ 10 Indicators

Not investment advice — read several signals together.

Indicators None active

Add lines over the price chart or a panel below it. Your choices are saved on this device.

Starter sets
Trend
Oscillators
Volume/volatility
Loading chart…

History limited by data provider; markers are heuristics, not signals.

Peer and sector context

No reviewed peer group is available for this symbol.

Balanced evidence

A deterministic summary of sourced facts—not an AI verdict.

Potential strengths

  • Latest SEC filing is Form 10-Q, filed 2026-02-12; review it for current changes and risks. SEC EDGAR ↗

Potential concerns

Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.

No accessible free API for these — links go to the source directly.

Morningstar MarketBeat

Financials

Income statement

Line item Dec '25Sep '25Mar '25Dec '24Sep '24Mar '24Dec '23Sep '23
Operating income -$2.6M -$2.3M -$1.9M -$2.6M -$2.4M -$1.7M -$2.8M -$2.5M
Net income -$2.0M -$2.2M -$1.7M -$2.5M -$2.2M -$1.7M -$2.7M -$2.5M
EPS (diluted) $-0.05 $-0.05 $-0.04 $-0.09 $-0.08 $-0.06 $-0.11 $-0.10
EPS (basic) $-0.05 $-0.05 $-0.04 $-0.09 $-0.08 $-0.06 $-0.11 $-0.10

Balance sheet

Line item Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24
Total assets $9.4M $10.7M $12.1M $14.0M $15.8M $2.5M $4.1M $6.0M
Total liabilities $1.5M $963.8K $487.7K $546.0K $878.8K $569.2K $260.6K $1.0M
Stockholders' equity $7.9M $9.7M $11.7M $13.5M $15.0M $1.9M $3.8M $5.0M
Total current assets $9.3M $10.5M $12.0M $13.8M $15.4M $2.0M $3.5M $5.4M
Total current liabilities — — — — — — — —
Cash & equivalents $9.0M $10.4M $11.6M $13.3M $15.0M $1.4M $3.1M $5.1M

Cash flow

Line item Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24
Operating cash flow -$1.3M -$1.3M -$1.7M -$1.6M -$1.4M -$1.7M -$2.1M -$1.5M
Financing cash flow — — $0 -$116.7K $15.0M — $0 $0
Share-based compensation $198.5K $237.6K $1.2M $300.0K $564.3K $286.9K $548.1K $200.0K
Change in accounts payable -$52.7K $383.4K -$203.4K $145.7K $29.8K $95.7K -$228.5K $66.2K

Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.

Institutional holders

SEC Form 13F filers holding ANEB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.

No 13F institutional ownership reported for this symbol.

Insider activity

Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-11-13 to 2024-12-23

Recent transactions

  • Most recent: English Aron R. (Director) — Open market purchase of 10,101,010 shares on 2024-12-23.

Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.

Insider purchases & sales, last 6 months

Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0

Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.

Insider roster

NameTitleMost Recent TransactionDateShares
English Aron R.DirectorOpen market purchase2024-12-2310,101,010

Recent transactions

DateInsiderTitleTransactionSharesPrice
2024-12-23English Aron R.DirectorOpen market purchase 10,101,010$0.99

Recent SEC filings

Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR submissions · updated 2026-10-22 02:16 UTC

FiledFormReport periodOfficial filing
2026-02-1210-Q2025-12-31 View on SEC.gov →
2026-02-128-K2026-02-12 View on SEC.gov →
2026-02-068-K2026-02-05 View on SEC.gov →
2026-01-298-K2026-01-29 View on SEC.gov →
2026-01-278-K2026-01-26 View on SEC.gov →
2025-12-228-K2025-12-22 View on SEC.gov →
2025-11-1310-Q2025-09-30 View on SEC.gov →
2025-11-138-K2025-11-13 View on SEC.gov →
2025-09-2910-K2025-06-30 View on SEC.gov →
2025-09-298-K2025-09-29 View on SEC.gov →
2025-09-128-K2025-09-12 View on SEC.gov →
2025-07-238-K2025-07-23 View on SEC.gov →

Headlines about ANEB (Anebulo Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.

SEC filings ↓

← Back to the full dashboard · My watchlist